There are approximately 21 million cases of typhoid fever worldwide, with a particularly high incidence in Asia. An estimated 220,000 deaths per year occur as a consequence of the disease (11) .
This article describes the extent and pattern of drug resistance of Salmonella enterica serovar Typhi across Asia. This information is vital for guiding treatment and is also important for helping policy makers to plan vaccination campaigns. The emergence and spread of drug resistance have limited treatment options for typhoid fever in many countries.
Since the isolation of multidrug-resistant (MDR) serovar Typhi strains which show resistance to all first-line antibiotics (chloramphenicol, ampicillin, and trimethoprim-sulfamethoxazole) in the 1980s, the fluoroquinolone class of antibiotics has become the treatment of choice for enteric fever (4, 38) . Unfortunately, outbreaks of serovar Typhi strains that were resis-tant to nalidixic acid (the prototype quinolone, which is used for in vitro screening tests) and showed reduced susceptibility to the fluoroquinolones have been reported subsequently in a number of countries (25) . Vietnam and particularly the Mekong Delta region of Vietnam faced a series of typhoid fever epidemics over the last decade, imposed on a background of endemic disease, that reflected changes in resistance patterns and pointed to a serious problem of drug resistance (24) . MDR is associated with a transferable plasmid (36) , while reduced susceptibility to the fluoroquinolones in serovar Typhi is usually associated with point mutations in the bacterial target genes encoding DNA gyrase and/or DNA topoisomerase IV.
This study describes the magnitude and patterns of drug resistance in 1,393 serovar Typhi strains isolated from 1993 to 2005 in Vietnam and from a cross-sectional sample set of 381 serovar Typhi strains isolated in 2002 to 2004 in eight Asian countries (Bangladesh, China, India, Indonesia, Laos, Nepal, Pakistan, and central Vietnam). These countries are home to more than 80% of the world's typhoid fever cases (11) . We defined the molecular mechanism of nalidixic acid resistance and performed in vitro bacterial time-kill experiments with isolates that harbored the common mutations in the gyrA gene. The time-kill experiments allowed us to model the impact of the gyrA mutations on the time course of the antimicrobial effects of older (ofloxacin) and newer-generation (gatifloxacin) fluoroquinolones.
(This work was presented in part at the American Meeting of Hygiene and Tropical Medicine, Atlanta, GA, December 2005.)
MATERIALS AND METHODS

Bacterial isolates. (i) Serovar Typhi strains isolated in southern
Vietnam from 1993 to 2005. One thousand three hundred ninety-three serovar Typhi isolates were collected consecutively from patients with uncomplicated typhoid fever during prospective hospital-based clinical studies between 1993 and 2005 conducted at Dong Thap Provincial Hospital, Dong Nai Peadiatric Hospital, An Giang Provincial Hospital, and the Hospital for Tropical Diseases, Ho Chi Minh City, all located in southern Vietnam. These studies have been described previously (7, 8, 23, 26, (32) (33) (34) (35) .
( (27) . One hundred eighty-two serovar Typhi isolates were collected as part of populationbased prospective surveillance studies conducted by multiple teams in collaboration with the International Vaccine Institute (IVI), Seoul, South Korea (1). These surveillance sites included whole townships (China and Vietnam), specific slum areas (Bangladesh, Pakistan, and India), and an impoverished urban subdistrict (Indonesia). Forty isolates were collected from February till December 2003 in an urban slum in Dhaka, Bangladesh; the setting has been described (5) All serovar Typhi isolates were collected consecutively from febrile patients during the indicated periods and came from geographically contiguous areas. The isolates were unselected and were representative of the population they came from.
Identification and antimicrobial susceptibilities. Isolates were identified using the API20E biochemical identification system (bioMerieux, Paris, France). Serology was carried out using specific antisera (polyvalent O, O9, Hd, and Vi) (Murex, Dartford, United Kingdom).
Antimicrobial susceptibility testing with ampicillin, chloramphenicol, trimethoprim-sulfamethoxazole, nalidixic acid, ofloxacin, ciprofloxacin, gatifloxacin, and ceftriaxone was performed by disc diffusion according to Clinical and Laboratory Standards Institute (CLSI) methods (10) and interpreted following CLSI guidelines (9) . The control strains used for all susceptibility tests were Escherichia coli ATCC 25922, Pseudomonas aeruginosa ATCC 27853, and Staphylococcus aureus ATCC 29213. MICs were determined by using the E-test (AB Biodisk, Solna, Sweden). MDR of isolates was defined as resistance to chloramphenicol (MIC Ն 32 g/ml), ampicillin (MIC Ն 32 g/ml), and trimethoprimsulfamethoxazole (MIC Ն 8/152 g/ml). Nalidixic acid resistance was defined as a MIC of Ն32 g/ml. The breakpoints for ofloxacin and gatifloxacin were Յ2 g/ml (susceptible) and Ն8 g/ml (resistant), and for ciprofloxacin, Յ1 g/ml (susceptible) and Ն4 mg/ml (resistant) (9) . All tests were performed at the Hospital for Tropical Diseases (HTD), Ho Chi Minh City, Vietnam, except for the isolates from Nepal, which were tested at Patan Hospital, Kathmandu, Nepal, using identical methods.
DNA isolation. A single colony was inoculated in 6 ml of LB broth (Sigma) and incubated overnight at 37°C. DNA was extracted using the Qiagen Genomic-tip 100/G and Genomic DNA buffer set (Qiagen, Ltd., Hilden, Germany) or the cetyltrimethylammonium bromide method of DNA extraction (2) . DNA stock was stored at Ϫ20 and Ϫ80°C. Four hundred nanograms of DNA was used for each PCR.
PCR and sequencing. Oligonucleotide primer pairs are shown in Table 1 . PCR amplifications of gyrA (347 bp), gyrB (345 bp), parC (270 bp), and parE (240 bp) were performed with 30 cycles of denaturation at 92°C for 1 min, annealing at 62°C for 1 min, and extension at 74°C for 2 min, followed by a final extension step at 74°C for 1 min.
PCR products were purified using the QIAquick PCR purification kit (Qiagen GmbH, Hamburg, Germany) and used directly as templates for sequencing, which was performed with the CEQ DTCS-Quick Start kit and analyzed using an automated sequencer, the CEQ8000 genetic analysis system (Beckman Coulter, Inc., Fullerton, CA).
Selected strains were screened for the presence of the qnrA and qnrS genes by PCR. The PCR conditions for the amplification of qnrS were as follows: 94°C for 2 min; 34 cycles of 94°C for 45 s, 48°C for 45 s, and 72°C for 45 s; final extension at 74°C for 5 min. PCR conditions for qnrA were identical except for the annealing temperature, which was 53°C. The positive control used was a Citrobacter sp. isolate (identified by API20E) harboring both the qnrA and qnrS genes, as confirmed by sequencing of PCR products.
In vitro time-kill analysis. All time-kill experiments were determined in duplicate. Ofloxacin powder was purchased from Sigma, Steinheim, Germany, and gatifloxacin powder was provided from Bristol-Myers Squibb, New Brunswick, NJ. Three serovar Typhi colonies were taken and inoculated in 10 ml MuellerHinton broth (Oxoid, Basingstoke, United Kingdom) at 37°C for 15 to 18 h. Two drops of this broth were inoculated into 10 ml of Mueller-Hinton broth and incubated at 37°C for 1 h to give 2 ϫ 10 6 CFU/ml. Ten milliters of MuellerHinton broth containing ofloxacin or gatifloxacin at 32ϫ MIC was added at time zero to give a final concentration of 16ϫ MIC; serial twofold dilutions were used a Sequences for the qnrS primers were designed based on the sequence of Shigella flexneri (17) .
to obtain 8ϫ, 4ϫ, 2ϫ, and 1ϫ MIC. The growth control contained no antibiotic. The cultures were incubated at 35 to 37°C for 24 h. Viable counts were measured immediately prior to the addition of the antibiotic and at 30 min and 1, 2, 4, 6, 8, and 24 h after the addition of the antibiotic. Viable counts were performed by using the Miles and Misra technique on nutrient agar plates following serial dilution in maximum-recovery diluents (Oxoid, United Kingdom). The lower limit of detection was 10 1 CFU/ml. Nucleotide sequence accession numbers. The partial DNA sequences of the gyrA gene of serovar Typhi AG 152 and DT 18 have been registered in the GenBank nucleotide sequence database under the accession numbers EF680460 and EF680461, respectively. (Fig. 1) .
RESULTS
Antimicrobial susceptibility testing. (i) Serovar
The antimicrobial susceptibility data of 202 serovar Typhi isolated in 2004 in southern Vietnam are shown in more detail in Table 2 .
( (Table 2 ). There were various rates of MDR across the sites, ranging from 16% (8/50) of isolates from Laos to 37.5% (15/40) from Bangladesh. China and Indonesia were exceptions, with no MDR serovar Typhi identified.
The percentages of nalidixic acid-resistant serovar Typhi isolates ranged from 0% in Indonesia and Laos and 4.8% (1/21) in China to 51% (76/149) in Nepal ( Table 2 ). The com- In Nepal, 18.1% (27/149) of serovar Typhi isolates were resistant to chloramphenicol and nalidixic acid. However, using current CLSI breakpoints, all isolates remained susceptible in vitro to ciprofloxacin and ofloxacin, with the exception of one isolate from southern Vietnam, AG 152, with intermediate susceptibility (MIC, 3.0 g/ml) to ofloxacin (Table 3 ) and six isolates (4%) from Nepal that were ciprofloxacin resistant. The highest MICs of gatifloxacin at which 50% and 90% of serovar Typhi isolates were inhibited were 0.125 l/ml and 0.25 l/ml, respectively ( Table 2 ). All isolates were susceptible to ceftriaxone.
DNA sequence analysis of QRDR of DNA gyrase and DNA topoisomerase IV and effect of mutations on fluoroquinolone susceptibility. One hundred twenty-seven nalidixic acid-resistant serovar Typhi isolates (118 from southern Vietnam, 5 from India, and 4 from Pakistan) with reduced susceptibilities to the fluoroquinolones (MIC of ofloxacin ranging from 0.5 g/ml to 3 g/ml) were selected for molecular analysis of the quinolone resistance determining region (QRDR) of gyrA. Six different types of mutations were detected. The most prevalent amino acid substitution was Ser833Phe (TCC3TTC) in 117/ 127 (92.1%) strains. Four isolates (3.1%) had an alteration at codon 83 changing Ser to Tyr (TCC3TAC). Two isolates showed the Asp873Gly (GAC3GGC) substitution and two isolates the Asp873Ala (GAC3GCC) substitution. Two serovar Typhi isolates had double-amino-acid substitutions in GyrA: isolates DT 18 (Ser833Phe and Asp873Gly) and AG 152 (Ser833Phe and Asp873Asn), as shown in Table 3 .
Fifty-five of these strains were analyzed for mutations in the QRDR of gyrB, parC, and parE (13, 20) ; no mutations were detected (Table 3) . Twenty-five isolates (indicated with an asterisk in Table 3 ) were screened for the presence of the plasmid-mediated quinolone resistance genes qnrA and qnrS (15) ; none were detected in these isolates.
In vitro time-kill analysis. One isolate representing each mutation group was selected for in vitro time-kill experiments: CT 76, wild-type strain (MICs, 0.064 g/ml for ofloxacin and 0.008 g/ml for gatifloxacin); HTD 798 (Ser833Phe; MICs, 1.0 g/ml for ofloxacin and 0.13 g/ml for gatifloxacin); CT 144 (Asp873Gly; MICs, 1 g/ml for ofloxacin and 0.094 g/ml for gatifloxacin); and DT 18 (Ser833Phe and Asp873Gly; MICs, 2.0 g/ml for ofloxacin and 0.25 g/ml for gatifloxacin). The mean changes in log 10 CFU/ml are presented in Fig. 2 . Ofloxacin showed rapid killing of wild-type strain CT 76 (Fig. 2a) ; viable counts of serovar Typhi HTD 798 and CT 144 decreased after 4 h at 4ϫ MIC, but complete killing could not be achieved (Fig. 2b and c) . No bactericidal activity was achieved against serovar Typhi DT 18 (Fig. 2d) . Gatifloxacin at 4ϫ MIC decreased the bacterial population of CT 76, HTD 798, and CT 144 (Fig. 2e, f, and g ) in the first 30 min and showed complete killing after 6 h. Viable counts of serovar Typhi DT 18 decreased after 4 h, followed by regrowth; higher concentrations (8ϫ or 16ϫ MIC) showed a more pronounced bactericidal effect against this double mutant (Fig. 2h) . In 1993, during the initial outbreak of MDR serovar Typhi in Kien Giang province in the south of Vietnam, the fluoroquinolone antibiotics were introduced for the treatment of typhoid fever (22) . Since 1993, the proportion of MDR serovar Typhi has remained at high levels and there has been a dramatic increase in nalidixic acid resistance. In 1998, 5 years after ofloxacin and ciprofloxacin become widely available in an uncontrolled market, 87% of the isolates were resistant to nalidixic acid; this increased to 97% by 2004. The combination of MDR and nalidixic acid resistance is a particular problem in Vietnam, because it severely restricts the therapeutic options for patients with typhoid fever.
Patients infected with nalidixic acid-resistant serovar Typhi show poor clinical response, high failure rates (up to 36%), and prolonged fecal carriage when treated with an older-generation fluoroquinolone, such as ofloxacin (8, 26) . The antimicrobial resistance data from southern Vietnam are complemented by the results of a cross-sectional study from eight Asian countries: Bangladesh, China, India, Indonesia, Laos, Nepal, Pakistan, and Vietnam. These countries are home to approximately 80% of the world's typhoid fever cases (11) .
While in southern Vietnam the MDR phenotype of serovar Typhi has remained at high levels over the last 13 years, there have been reports of a return to chloramphenicol sensitivity in some regions (12, 21) . However, in our study the prevalence of chloramphenicol resistance remained high in many Asian countries (18% in Laos, 19% in Nepal, 26% in India and Pakistan, and 40% in Bangladesh), with the exception of China and Indonesia.
In 2002 to 2004, all countries in the region, with the exception of China and Laos, faced a problem of nalidixic acid resistance, with southern Vietnam as a particular hot spot. Roumagnac et al. recently suggested that fluoroquinolone use has driven the clonal expansion of a nalidixic acid-resistant serovar Typhi haplotype, H58, in Southeast Asia (29) . The emergence of resistance of serovar Typhi to ciprofloxacin (6/ 149 isolates; 4%) in Nepal, together with reports of high-level ciprofloxacin resistance in India and Bangladesh (14, 28, 30) , might be the prelude to a worsening drug resistance problem in Asia.
In this study carried out across Asia, mutations associated with nalidixic acid resistance and reduced susceptibility to fluoroquinolones for serovar Typhi were defined only in gyrA, as single-amino-acid substitutions at either codon 83 or 87 (6, 18, 31, 37) , with the exception of two isolates from Vietnam, which had double-amino-acid substitutions. There have been two recent reports of serovar Typhi with the Ser83Phe and Asp87Gly double alteration in high-level-ciprofloxacin-resistant serovar Typhi (28, 30) . In our study, the isolates with double mutations in gyrA were less susceptible to the fluoroquinolones, and this phenotype may become more widespread in the future if continued drug pressure is applied. This is a particular problem in many parts of Asia, where antibiotics are readily available in an unregulated marketplace and inadequate doses and durations of antibiotics are often used. Our time-kill experiments suggest that the choice of the fluoroquinolone and the dose used for the treatment of serovar Typhi may be critical and underline that clearly not all the fluoroquinolones are as susceptible to these common mutations. Continued use of the older-generation fluoroquinolones (ofloxacin and ciprofloxacin) may encourage the persistence of resistant isolates and lead to the development of new mutations which might compromise the efficacy of the newer generation. With lower MICs and better responses in the time-kill experiments, it is possible that gatifloxacin (and potentially other newer-generation fluoroquinolones) would prove a better choice for use in typhoid fever. This provides a clear rationale for the clinical assessment of these drugs in randomized controlled trials in typhoid fever. If these in vitro data are supported by clinical results, then this newer generation of fluoroquinolones should be recommended for the treatment of typhoid fever instead of ciprofloxacin and ofloxacin.
In conclusion, the emergence and persistence of MDR and nalidixic acid-resistant serovar Typhi strains constitute a major problem across Asia. No drug has ever been developed specifically for typhoid fever, and there are very few potential targets in Salmonella against which new drugs could be designed (3) . We need to use our current drugs better and use the best and most affordable drugs available in order to prevent further resistance. Knowledge of the extent of drug resistance should be an important factor when discussing the implementation of a comprehensive typhoid vaccination strategy.
